Reply to: "Cost-effectiveness of upcoming treatments for hepatitis C: we need to get the models right"

J Hepatol. 2014 Aug;61(2):454-5. doi: 10.1016/j.jhep.2014.05.006. Epub 2014 May 10.

Authors

Zobair M Younossi¹, Linda Henry², Mendel Singer³

Affiliations

¹ Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, USA; Betty & Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, USA. Electronic address: zobair.younossi@inova.org.
² Betty & Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, USA.
³ Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH, USA.

PMID: 24824281
DOI: 10.1016/j.jhep.2014.05.006

No abstract available

Publication types

Letter
Comment

MeSH terms

Antiviral Agents / administration & dosage*
Hepatitis C, Chronic / drug therapy*
Humans

Substances

Antiviral Agents